13C NMR study of the effects of leptin treatment on kinetics of hepatic intermediary metabolism.
The recent discovery of leptin receptors in peripheral tissue raises questions about which of leptin's biological actions arise from direct effects of the hormone on extraneural tissues and what intracellular mechanisms are responsible for leptin's effects on carbohydrate and lipid metabolism. The present study is focused on the action of leptin on hepatic metabolism. Nondestructive 13C NMR methodology was used to follow the kinetics of intermediary metabolism by monitoring flux of 13C-labeled substrate through several multistep pathways. In perfused liver from either ob/ob or lean mice, we found that acute treatment with leptin in vitro modulates pathways controlling carbohydrate flux into 13C-labeled glycogen, thereby rapidly enhancing synthesis by an insulin-independent mechanism. Acute treatment of ob/ob liver also caused a rapid stimulation of long-chain fatty acid synthesis from 13C-labeled acetyl-CoA by the de novo synthesis route. Chronic leptin treatment in vivo induced homeostatic changes that resulted in a tripling of the rate of glycogen synthesis via the gluconeogenic pathway from [2-13C]pyruvate in ob/ob mouse liver perfused in the absence of the hormone. Consistent with the 13C NMR results, leptin treatment of the ob/ob mouse in vivo resulted in significantly increased hepatic glycogen synthase activity. Chronic treatment with leptin in vivo exerted the opposite effect of acute treatment in vitro and markedly decreased hepatic de novo synthesis of fatty acids in ob/ob mouse liver. In agreement with the 13C NMR findings, activities of hepatic acetyl-CoA carboxylase and fatty acid synthase were significantly reduced by chronic treatment of the ob/ob mouse with leptin. Our data represent a demonstration of direct effects of leptin in the regulation of metabolism in the intact functioning liver.
Cohen
S M
SM
Merck Research Laboratories, Biochemistry and Physiology, P.O. Box 2000, Rahway, NJ 07065, USA. sheila_cohen@merck.com
Werrmann
J G
JG
Tota
M R
MR
D000818:Animals; D005227:Fatty Acids / Q000096:biosynthesis*; D018698:Glutamic Acid / Q000378:metabolism; D066298:In Vitro Techniques; D007657:Ketone Bodies / Q000378:metabolism; D007700:Kinetics; D020738:Leptin; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008112:Liver Glycogen / Q000096:biosynthesis*; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese; D008954:Models, Biological; D009765:Obesity / Q000378:metabolism; D011506:Proteins / Q000494:pharmacology*; D015854:Up-Regulation
D005227:Fatty Acids; D007657:Ketone Bodies; D020738:Leptin; D008112:Liver Glycogen; D011506:Proteins; D018698:Glutamic Acid